Sembragiline

Sembragiline (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code names EVT-302, RG-1577, RO-4602522) is a selective and reversible monoamine oxidase B (MAO-B) inhibitor which is or was under development for the treatment of Alzheimer's disease.^[1][2][3][4] It was also under development for the treatment of smoking withdrawal, but development for this indication was discontinued.^[1][2][3] The drug is taken by mouth.^[1][4] Sembragiline is or was being developed by Roche and Evotec SE.^[1][2][3]

Other namesEVT-302; EVT302; RG-1577; RG1577; RO-4602522; RO4602522

Routes of
administrationOral^[1]

Drug classReversible monoamine oxidase B (MAO-B) inhibitor

CAS Number

• 676479-06-4

Quick facts Clinical data, Other names ...

Sembragiline

Clinical data
Other names	EVT-302; EVT302; RG-1577; RG1577; RO-4602522; RO4602522
Routes of administration	Oral[1]
Drug class	Reversible monoamine oxidase B (MAO-B) inhibitor
Identifiers
IUPAC name N-[(3S)-1-[4-[(3-fluorophenyl)methoxy]phenyl]-5-oxopyrrolidin-3-yl]acetamide
CAS Number	676479-06-4
PubChem CID	10246762
ChemSpider	8422249
UNII	K3W9672PNJ
KEGG	D11224
ChEMBL	ChEMBL3707394
Chemical and physical data
Formula	C19H19FN2O3
Molar mass	342.370 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(=O)N[C@H]1CC(=O)N(C1)C2=CC=C(C=C2)OCC3=CC(=CC=C3)F
InChI InChI=1S/C19H19FN2O3/c1-13(23)21-16-10-19(24)22(11-16)17-5-7-18(8-6-17)25-12-14-3-2-4-15(20)9-14/h2-9,16H,10-12H2,1H3,(H,21,23)/t16-/m0/s1 Key:VMAVCCUQTALHOB-INIZCTEOSA-N

Close